DIRS.INFO The most relevant business & tech news

☆ Cathie Wood positions for new tech boom - and it doesn't matter who wins the White House
▼ + stars: | 2024-11-05 | by ( Stephanie Landsman | ) www.cnbc.com time to read: +2 min

ARK Invest's Cathie Wood is positioning for a White House administration that embraces transformative technology. Wood runs the firm's flagship ARK Innovation ETF (ARKK) — which is up almost 22% over the past three months. After soaring nearly 68% last year, the ARK Innovation ETF is down about 8% in 2024. Wood is also behind the ARK Genomic Revolution ETF (ARKG) , which is down about 25% so far this year. The ARK Genomic Revolution ETF owns both stocks.

Persons: Wood, it's, Joe Biden, ARKK Organizations: White, Innovation, Federal Reserve, Tech, Genomic, Beam Therapeutics Locations: ARKK

☆ With AI warning, Nobel winner joins ranks of laureates who’ve cautioned about the risks of their own work
▼ + stars: | 2024-10-13 | by ( Meg Tirrell | ) edition.cnn.com time to read: +10 min

Hinton isn’t the first Nobel laureate to warn about the risks of the technology that he helped pioneer. Irene Joliot-Curie and Frederic Joliot shared the Nobel Prize for chemistry in 1935. AFP/Getty Images1945: Antibiotic resistanceSir Alexander Fleming shared the 1945 Nobel Prize in medicine with Ernst Chain and Sir Edward Florey for the discovery of penicillin and its application in curing bacterial infections. “I, for one, would not shrink from that challenge.”Jennifer Doudna won the Nobel Prize in chemistry in 2020 for her work on a new method of gene editing. Nobel Prize Outreach/Brittany Hosea-Small/Handout/Reuters2020: Gene editingFour years ago, Jennifer Doudna and Emmanuelle Charpentier shared the Nobel Prize in chemistry for the development of a method for genome editing called CRISPR-Cas9.

Persons: Geoffrey Hinton, ”, ” Hinton, John Hopfield “, Hinton, Hinton isn’t, Irene Joliot, Curie, Frederic Joliot, Marie, Pierre Curie, Joliot, “, Sir Alexander Fleming, Ernst Chain, Sir Edward Florey, Fleming, underdose, Jeffrey Gerber, ” Gerber, ” Paul Berg, Tobbe, Paul Berg, Berg, Joanna Rose, it’s, Jesse Gelsinger, ” Jennifer Doudna, Brittany Hosea, Gene, Jennifer Doudna, Emmanuelle Charpentier, ” Doudna, “ We’ve, ” CNN’s Christian Edwards, Katie Hunt Organizations: CNN, Google, University of Toronto, Princeton University, Hulton, Getty, Children’s Hospital of Philadelphia, World Health Organization, Nobel, Innovative Genomics Institute Locations: AFP, ”, Stockholm

☆ How did a rose get its prickles? A new study has answers
▼ + stars: | 2024-08-01 | by ( Taylor Nicioli | ) edition.cnn.com time to read: +8 min

Prickles have been around for at least 400 million years, dating back to when ferns and their relatives emerged with some bearing prickles on their stems. Lonely Guy genesBy removing prickles from various species, including roses and eggplants, the authors found that a LOG gene was responsible for the prickles in about 20 types of plants studied. LOG-related genes are found in all plants, even dating back to mosses, which are regarded as the first dry-land plant, Lippman said. “(LOG genes) have been repeatedly co-opted (a biological shift in a trait’s function) in different plant species for the formation of prickles, and also repeatedly lost in lineages where prickles are lost. For agricultural purposes, removing prickles could make harvesting easier and pave the way to get lesser-known produce into grocery stores.

Persons: munch, Zachary Lippman, —, Lippman, Guy, It’s, ” Lippman, “, Tyler Coverdale, ” Coverdale, Coverdale, ”, Vivian Irish Organizations: CNN, Laboratory, University of Utah, Wings, Howard Hughes Medical Institute, University of Notre Dame, Yale Locations: Long, , New York, Yale University’s, Australia

☆ How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot
▼ + stars: | 2024-07-24 | by ( Alistair Barr | ) www.businessinsider.com time to read: +11 min

Louis Lehot, a Silicon Valley law-firm partner, specializes in taking companies from startup to IPO. The IPO market is expected to pick up later this year, so Business Insider emailed Silicon Valley lawyer Louis Lehot, a partner at Foley & Lardner, for advice on how startups should prepare for life as public companies. Are public market investors generally keen to invest in IPOs, or are they focused elsewhere? Public market investors are selective, focusing on established profitability and sustainable growth over speculative, high-growth stories. What are the key process changes companies need to make ahead of an IPO?

Persons: Louis Lehot, Lehot, —, Lardner, Collison Organizations: Service, Foley, Healthcare, Biotech, Green Energy, Enterprise, Street, Investor

☆ Nobel Prize-winning chemist Thomas R. Cech on ‘The Catalyst’ and the future of RNA
▼ + stars: | 2024-06-05 | by ( Saira Mueller | ) edition.cnn.com time to read: +13 min

“We saw that with the mRNA (messenger RNA) vaccines that it can be a good messenger,” says Cech. The Catalyst by Thomas R. Cech W W NortonYou mentioned in “The Catalyst” that research on RNA has been around since the ‘50s. What is something that most people get wrong about mRNA vaccines, such as the Covid-19 ones? Thomas R. Cech in a lab in 1984, five years before he won the Nobel Prize in Chemistry. How does this apply to DNA, RNA, mRNA and CRISPR?

Persons: you’re, ”, Thomas R, Cech, ” Cech, Sidney Altman, he’s, Norton, It’s, Thomas R . Cech, — Organizations: CNN, Pfizer, DNA, University of Colorado, Denver Post, Rotary Clubs, Lions Locations: Moderna, University of Colorado , Boulder, Boulder , Colorado, China, Cambridge , Massachusetts, United States, Germany

☆ Meme stocks are having a moment, but the broader market is rallying as well
▼ + stars: | 2024-05-14 | by ( Bob Pisani | ) www.cnbc.com time to read: +2 min

Meme stocks are having a moment, but the broader market is rallying as well. While GameStop's 74% rally got a lot of attention Monday ( "meme stocks are back!" ), the evidence indicates that a broad rally is dragging up a lot of stuff that hasn't been performing well this year. The S & P 600 Small Cap advance/decline is also near the highest levels since December, while the S & P Mid Cap 400 advance/decline line is at a new high. So when you hear the tired old refrain, "meme stocks are back," take a look at the rest of the market.

Persons: hasn't, Marko Kolanovic, Morgan, BoE, Ryan Detrick Organizations: Fed, ECB, Intel, Nike, Comcast, ChargePoint Holdings, CRISPR Therapeutics, Unity Software, Carson Group, CNBC

☆ Experimental gene therapy restores some vision in patients with inherited blindness
▼ + stars: | 2024-05-06 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +16 min

“Now, post-surgery and post recovery, I am able to see in dimmer lighting with my left eye,” Cook said. A treatment that used CRISPR was found to be safe and efficacious in improving vision among a small sample of patients with inherited blindness in the Phase 1/2 clinical trial that Cook participated in. Months following the treatment, Cook was sitting with friends on a balcony that had Christmas lights wrapped around the railing. Courtesy Olivia CookBefore the treatment, Cook said that she sometimes could conceal the vision challenges she has had. Mass Eye and EarKalberer described the CRISPR treatment as “groundbreaking,” but warned it’s not a cure.

Persons: Olivia Cook, Cook, ”, ” Cook, “, I’ve, “ I’d, you’d, CRISPR, Eric Pierce, Brigham, “ We’re, ” Pierce, Jason Comander, ‘, Michael Kalberer, Kalberer, it’s, “ It’s, It’s, Pierce, Editas, We’re, Art Caplan, ” Caplan, —, Vlad Diaconita, ” Diaconita, Dr, Sanjay Gupta, Aliaa Abdelhakim Organizations: CNN, Missouri State University, New England, of Medicine, Mass, Harvard Medical School, Editas Medicine, Perelman School of Medicine, University of Pennsylvania, University of Michigan, University of Miami, Oregon Health & Science University, US Food and Drug Administration, CEP290, pharma, NYU Grossman School, Medicine’s Department of Population Health, Columbia University Vagelos College of Physicians and Surgeons, CNN Health Locations: Springfield, United States, CEP290

☆ Citi names 3 biotech stocks to play a growing $2.9 billion opportunity — giving one about 50% upside
▼ + stars: | 2024-05-01 | by ( Weizhen Tan | ) www.cnbc.com time to read: +2 min

The outlook is starting to look bright for biotech stocks, according to some. With markets now expecting the first rate cut to be in September rather than June or July, as previously thought, biotech stocks could start to do well. Biotech encompasses many different areas, but Citi has identified one with a $2.9 billion market — which it says is set for even more growth. It gave CSL a price target of $305, or nearly 11% potential upside. It gave Intellia a price target of $31, or 49% potential upside.

Persons: Morgan Stanley, Garadacimab, Ionis, Citi Organizations: Biotech, Citi, Ionis Pharmaceuticals, Intellia Therapeutics, CSL, Intellia

☆ Generative A.I. Arrives in the Gene Editing World of CRISPR
▼ + stars: | 2024-04-22 | by ( Cade Metz | ) www.nytimes.com time to read: +1 min

Generative A.I. technologies can write poetry and computer programs or create images of teddy bears and videos of cartoon characters that look like something from a Hollywood movie. Now, new A.I. The company is expected to present the paper next month at the annual meeting of the American Society of Gene and Cell Therapy. Much as ChatGPT learns to generate language by analyzing Wikipedia articles, books and chat logs, Profluent’s technology creates new gene editors after analyzing enormous amounts of biological data, including microscopic mechanisms that scientists already use to edit human DNA.

Persons: ChatGPT Organizations: American Society of Gene, Cell Locations: Berkeley, Calif

☆ Why don’t humans have tails?
▼ + stars: | 2024-03-23 | by ( Mindy Weisberger | ) edition.cnn.com time to read: +10 min

One of those led to shorter tails; the more of that protein the genes produced, the shorter the tails. A tail as old as timeFor modern humans, tails are a distant genetic memory. While Alu’s role “seems to be a very important one,” other genetic factors likely contributed to the permanent disappearance of our primate ancestors’ tails,” Xia said. In their experiments, the researchers found that when mice were genetically engineered for tail loss, some developed neural tube deformities that resembled spina bifida in humans. “Maybe the reason why we have this condition in humans is because of this trade-off that our ancestors made 25 million years ago to lose their tails,” Yanai said.

Persons: —, Alu, AluY, Bo Xia, ” Xia, ”, Xia, Itai Yanai, ” Yanai, “, Bo, Yanai, TBXT’s, Liza Shapiro, ” Shapiro, africanus, Shapiro, spina, Mindy Weisberger Organizations: CNN, Gene, Broad Institute of MIT, Harvard University, Institute for Systems Genetics, New York University Grossman School of Medicine, University of Texas, Scientific Locations: Austin, Kenya

☆ Opinion | Democrats Need to Stop Playing Nice
▼ + stars: | 2024-03-11 | by ( Joe Klein | ) www.nytimes.com time to read: +1 min

There is a moment in the 2008 HBO movie “Recount” that illuminates an essential difference between Republicans and Democrats. Warren Christopher, a courtly former secretary of state, represents the Democratic candidate Al Gore. Democrats litigate; Republicans fight. Democrats float toward an almost helium-infused state of high-mindedness; Republicans see politics as a no-holds-barred cage match. But given the party’s recent history, the Democrats will probably need some CRISPR editing to their DNA.

Persons: Warren Christopher, Al Gore, “, ” James Baker, George W, Bush, Christopher, Baker, Biden’s Organizations: HBO, Democrats, Democratic, Democrats litigate, Republicans, Union Locations: Florida, United States, Biden’s pugilistic State

☆ Crispr Therapeutics CEO: Science in gene editing is moving at breakneck speed
▼ + stars: | 2024-02-29 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCrispr Therapeutics CEO: Science in gene editing is moving at breakneck speedSamarth Kulkarni, Crispr Therapeutics CEO, joins 'Power Lunch' to discuss the hurdles to getting rare disease drugs through regulation, what consumers can look forward to in gene editing, and much more.

Persons: Samarth Kulkarni Organizations: Crispr, Crispr Therapeutics

☆ Cramer's Lightning Round: 'Hard pass' on Surgery Partners
▼ + stars: | 2024-01-30 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Surgery Partners's year-to-date stock performance. Stock Chart Icon Stock chart icon Energy Transfer's year-to-date stock performance. Stock Chart Icon Stock chart icon DigitalOcean's year-to-date stock performance. Stock Chart Icon Stock chart icon Vodafone's year-to-date stock performance. Stock Chart Icon Stock chart icon MP Materials' year-to-date stock performance.

Persons: it's, they're, I'm Organizations: Surgery Partners, Energy, Vodafone, Verizon, Therapeutics, CRISPR Therapeutics

☆ Lightning Round: Still not too late to buy Energy Transfer, says Jim Cramer
▼ + stars: | 2024-01-30 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: Still not too late to buy Energy Transfer, says Jim Cramer'Mad Money' host Jim Cramer weighs in on stock including: Surgery Partners, Energy Transfer, DigitalOcean Holdings, Vodafone, CRISPR and MP Materials.

Persons: Jim Cramer Organizations: Energy, Surgery Partners, DigitalOcean Holdings, Vodafone, CRISPR, Materials

☆ More people need transplants than there are organ donors. Pigs might offer a solution
▼ + stars: | 2024-01-30 | by ( Jen Christensen | ) edition.cnn.com time to read: +23 min

The need for more transplant organs is immense and growing. Researchers have transplanted genetically modified pig kidneys and hearts into people who were brain-dead to test whether they work in humans. Although Larry Faucette was too sick for a human heart transplant, University of Maryland doctors said he seemed physically strong enough for a genetically modified pig heart. It was more than a decade after the first heart transplant but long before such procedures became relatively routine. “We learned that the pig heart is an adequate substitute for a human heart.

Persons: Lawrence Faucette, Ann, he’d, ” Ann, Larry Faucette, Ann Faucette Ann, Larry, didn’t, ”, Robert Montgomery, “, Shelby Lum, ” Montgomery, Xenotransplantation, Art Caplan, Caplan, Babe ”, ” Caplan, They’re, eGenesis, people’s, Dr, Mike Curtis, Sanjay Gupta, ” Curtis, hasn’t, Julie O’Hara, Jim Parsons, Jayme Locke, couldn’t, Locke, Parsons, NYU —, Montgomery —, O’Hara, ” Locke, David Bennett Sr, Mary, David Jr, Bartley Griffith, Bennett, they’ve, Muhammad M, Mohiuddin, Larry Faucette’s, David Bennett’s, ” Griffith, xenotransplantation Ann Faucette, Wilbur, White’s, Ann Faucette, NYU ethicist Caplan, they’re, NYU’s Montgomery, UAB’s Locke, Steve Wood, ’ Curtis, “ I’m, it’s, ” O’Hara, Bennett’s, Larry Faucette —, ” Bennett’s, Faucette, who’d, Griffith, would’ve, Kate, Lucy, Nadia Kounang Organizations: CNN, Food and Drug Administration, University of Maryland, FDA, National Institute of Allergy, NYU Langone Transplant Institute, NYU Langone's Transplant, NYU Grossman School, Medicine’s Department of Population Health, “ Disney, University of Alabama, Transplant Institute, Parsons Family, Birmingham, NYU, University of Maryland School of Medicine, Doctors, University of Maryland Medical Center, Uno, UAB, CNN Health, NFL Locations: Frederick , Maryland, United States, Montgomery, “, Midwest, Yucatan, Maryland

☆ Vertex non-opioid painkiller shows positive results in critical late-stage trial on acute pain
▼ + stars: | 2024-01-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Acute pain is usually caused by injury, surgery, illness, trauma or painful medical procedures and is likely to ease with time. Around 80 million patients are prescribed a medicine for their moderate-to-severe acute pain every year in the U.S., Vertex said in a release. Last year, the company's painkiller produced positive results in a mid-stage trial in diabetes patients suffering from a chronic nerve condition. Those two procedures are commonly used in studies of people with acute pain. Jefferies analyst Michael Yee said the drug's failure to meet that goal is in line with expectations and that overall, the late-stage trial results released Tuesday are positive.

Persons: Reshma Kewalramani, painkiller, Michael Yee Organizations: Vertex Pharmaceuticals, Food and Drug, Wall Street, CRISPR Therapeutics, Jefferies Locations: Boston, U.S

☆ US FDA approves Vertex/CRISPR gene therapy for an inherited blood disorder
▼ + stars: | 2024-01-17 | by ( ) www.cnbc.com time to read: +1 min

The headquarters of US biopharmaceutical company Vertex Pharmaceuticals in Boston, Massachusets, on November 4, 2023. The U.S. health regulator has approved Vertex Pharmaceuticals and CRISPR Therapeutics' gene therapy to treat a rare blood disorder requiring regular blood transfusions, in patients 12 years and older, Vertex said on Tuesday. The decision earns the therapy, branded as Casgevy, the second U.S. approval after it was greenlighted in December for sickle cell disease, another inherited blood disorder. The approval by the Food and Drug Administration comes more than two months ahead of its expected action date of March 30. Oppenheimer analyst Hartaj Singh said he expects a "slow and steady launch" for the therapy and estimated combined peak sales of about $400 million.

Persons: Oppenheimer, Hartaj Singh Organizations: Vertex Pharmaceuticals, Pharmaceuticals, CRISPR Therapeutics, Food and Drug Administration Locations: US, Boston, Massachusets, U.S, United States

☆ Cathie Wood’s Innovation ETF is up more than 30% in November, on pace for its best month ever
▼ + stars: | 2023-11-30 | by ( Yun Li | ) www.cnbc.com time to read: +1 min

Cathie Wood, CEO of Ark Invest, speaks during an interview on CNBC on the floor of the New York Stock Exchange on Feb. 27, 2023. Wood's flagship Ark Innovation ETF (ARKK) has rallied 32% this month, on pace to score its strongest month ever since its inception in 2014. The fund rebounded dramatically from three straight months of losses, pushing 2023 gains to 48%. Cathie Wood is about to notch her best month ever as her holdings of innovative technology stocks roared back from steep losses amid declining Treasury yields in November. Driving the innovation fund higher this month have been biotech names CRISPR Therapeutics and Twist Bioscience , along with Roku , Coinbase , Block and Shopify , which are all up at least 50%.

Persons: Cathie Wood, ARKK, Wood Organizations: Ark Invest, CNBC, New York Stock Exchange, Innovation, CRISPR Therapeutics, Twist, Ark, CNBC PRO Locations: outflows

☆ Cramer's Lighting Round: Buy Boeing
▼ + stars: | 2023-11-28 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

Stock Chart Icon Stock chart icon CRISPR's year-to-date stock performance. Stock Chart Icon Stock chart icon Dell's year-to-date stock performance. Stock Chart Icon Stock chart icon Cencora's year-to-date stock performance. Stock Chart Icon Stock chart icon T-Mobile's year-to-date stock performance. Stock Chart Icon Stock chart icon Boeing's year-to-date stock performance.

Persons: it's, Mike Sievert, Cardinal Health's, Tony Xu, Tony Organizations: Dell, Mobile, Boeing, Cardinal Locations: Cardinal

☆ Lightning Round: This is Boeing's year, says Jim Cramer
▼ + stars: | 2023-11-28 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: This is Boeing's year, says Jim Cramer'Mad Money' host Jim Cramer weighs in on stock including: CRISPR, Dell, Cencora, T-Mobile, Boeing, Cardinal Health, DoorDash and Macy's

Persons: Jim Cramer, Macy's Organizations: Dell, Mobile, Boeing, Cardinal Health

☆ UK regulators approve medical treatment involving CRISPR gene editing in world first
▼ + stars: | 2023-11-16 | by ( Katie Hunt | ) edition.cnn.com time to read: +4 min

CNN —The United Kingdom has become the first country to give regulatory approval to a medical treatment involving the revolutionary CRISPR gene editing tool. The treatment, made by Vertex Pharmaceuticals, is administered by taking stem cells out of a patient’s bone marrow and editing a gene in the cells in a lab. “Modifying the stem cells from the bone marrow of the patient avoids the problems associated with immune compatibility, i.e. The release from the MHRA did not say how much the treatment would cost, but it’s likely to be expensive. CRISPR-Cas9 has had a major impact on biomedical research, clinical medicine and agriculture and is widely used in labs around the world.

Persons: —, ”, Julian Beach, “, — Emmanuelle Charpentier, Jennifer A, Doudna —, Casgevy, Alena Pance, ” Pance, Cas9, Jiankui Organizations: CNN, country’s Medicines, Healthcare, Agency, Beta, Vertex Pharmaceuticals, US Food and Drug Administration, University of Hertfordshire, Science Media Centre Locations: United Kingdom, South Asian

LONDON (AP) — Britain's medicines regulator has authorized the world's first gene therapy treatment for sickle cell disease, in a move that could offer relief to thousands of people with the crippling disease in the U.K. The agency approved the treatment for patients with sickle cell disease and thalassemia who are 12 years old and over. Casgevy is currently being reviewed by the U.S. Food and Drug Administration; the agency is expected to make a decision early next month, before considering another sickle cell gene therapy. Millions of people around the world, including about 100,000 in the U.S., have sickle cell disease. Scientists believe being a carrier of the sickle cell trait helps protect against severe malaria.

Persons: ”, Helen O'Neill Organizations: Medicines and Healthcare Regulatory Agency, Vertex Pharmaceuticals, CRISPR Therapeutics, Helen O'Neill of University College London, Medicines, U.S . Food, Drug Administration, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: Europe, CRISPR, South Asian, Britain, U.S, Africa, India, Eastern

☆ Sickle-Cell Treatment Created With Gene Editing Wins U.K. Approval
▼ + stars: | 2023-11-16 | by ( Gina Kolata | More About Gina Kolata | ) www.nytimes.com time to read: +1 min

Regulators in Britain on Thursday approved the first treatment derived from CRISPR, the revolutionary gene-editing method. Called Casgevy, the treatment is intended to cure sickle-cell disease and a related condition, beta thalassemia. The companies anticipate that the Food and Drug Administration will approve Casgevy for sickle-cell patients in the United States in early December. The agency will decide on approval for beta thalassemia next year. That treatment does not rely on gene editing, insteading using a method that inserts new DNA into the genome.

Organizations: Vertex Pharmaceuticals, CRISPR Therapeutics, and Drug, Bluebird Bio Locations: Britain, Boston, Switzerland, United States, Somerville, Mass

☆ FDA panel says Vertex/CRISPR to assess safety risks of gene therapy in follow-up study
▼ + stars: | 2023-10-31 | by ( ) www.reuters.com time to read: +2 min

[1/2] A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston, Massachusetts, U.S., October 23, 2019. REUTERS/Brian Snyder/File Photo Acquire Licensing RightsOct 31 (Reuters) - A panel of advisers to the U.S. health regulator said on Tuesday Vertex Pharmaceuticals (VRTX.O) and CRISPR Therapeutics (CRSP.BN) could assess potential safety risks of their sickle cell disease gene therapy after approval. If the therapy is approved, Vertex has proposed a 15-year follow up of patients to evaluate the safety outcomes of the therapy. Patients who were treated with the therapy were free from severe vaso-occlusive crisis for 12 months from the infusion of exa-cel. "It was made pretty clear that any theoretical off-target editing concerns do not outweigh the benefits of drug approval," said Salim Syed, analyst at Mizuho.

Persons: Brian Snyder, Scot Wolfe, Salim Syed, Sriparna Roy, Krishna Chandra Organizations: Vertex Pharmaceuticals, REUTERS, CRISPR Therapeutics, Staff, U.S . Food, Drug Administration, UMass Chan Medical, Analysts, FDA, Mizuho, Thomson Locations: Boston , Massachusetts, U.S, Bengaluru

☆ A New Sickle Cell Treatment Will Change Lives — but How Many? - The New York Times
▼ + stars: | 2023-10-30 | by ( Daniela J. Lamas | ) www.nytimes.com time to read: +3 min

And though comprehensive sickle cell care — at dedicated centers with expert hematologists, social workers and pain management specialists — reduces hospitalizations, and is the standard for diseases like cystic fibrosis and hemophilia, which do not disproportionately affect Black people, these centers are few and far between for sickle cell. Into this complicated landscape enters the possibility of gene therapy. It’s important to note that this isn’t the first cure for sickle cell. is expected to review another gene therapy from the company Bluebird Bio that targets sickle cell disease but does not use CRISPR; this was the therapy Mr. Holmes received as part of the N.I.H. When she was 17 and hospitalized, facing the reality of her chronic illness, she told her mother that she was ready to pursue gene therapy.

Persons: Holmes, Elizabeth Ford, Ford Organizations: Vertex Pharmaceuticals, CRISPR Therapeutics, Bluebird

Search resuls for: "CRISPR"

25 mentions found